Omada Health (OMDA) announced the expansion of its integrated platform to include dedicated cholesterol management alongside weight, glucose, blood pressure, and GLP-1 support. Up to 70% of adults with obesity have high cholesterol, yet among U.S. adults with atherosclerotic cardiovascular disease, only 41% ever reached a healthy LDL-C level. This gap underscores a core challenge in traditional care models that are not designed to sustain the day-to-day behaviors required to improve cholesterol numbers over time. “Launching with a market-leading employer is a signal that there is a need for between-visit cholesterol care that properly addresses long-term cardiovascular risk in their populations,” said Sean Duffy, CEO & Co-Founder of Omada Health. “Because of our flexible infrastructure, we were able to quickly add cholesterol support on our existing platform, giving customers one partner for integrated cardiometabolic care in response to their demand.”
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OMDA:
- Omada Health: Sentiment-Driven Sell-Off Creates Compelling Entry Point Amid Accelerating Growth and Limited Policy Risk
- Omada Health: Strong 2025 Finish, GLP-1 Tailwinds, and Attractive 2026 Valuation Upside Support Reiterated Buy Rating
- Omada Health price target lowered to $26 from $29 at Goldman Sachs
- 3 ‘Strong Buy’ Biotech Stocks to Buy Today, 1/13/2026, According to Top Analysts
- Omada Health: Accelerating Membership and Revenue Growth Underpins Buy Rating and Upside Potential
